DEC 05, 2017 6:00 AM PST

WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

Sponsored by: Agilent
Speaker

Abstract

DATE: December 5th, 2017
TIME:  6:00AM PT

Androgen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Novel second generation enhanced androgen inhibitors, abiraterone acetate and enzalutamide, improve survival of CRPC patients following androgen deprivation therapy. However, a significant group of patients demonstrate primary resistance to these agents and other patients acquire resistance during therapy. The mechanisms of enhanced androgen inhibitor resistance are complex. AR-dependent mechanisms involve AR overexpression, AR mutation, intra-tumor ligand biosynthesis, modulation of co-activators and co-repressors and expression of AR spice variants. AR-independent tumors activate glucocorticoid receptor and differentiate to aggressive variant or neuroendocrine phenotype with loss of tumor suppressors.  Patient derived xenografts (PDX) developed from men with AR-positive or AR-negative CRPC were used to determine impact of AR signaling on glycolysis. We used two AR positive (MDA-PCa-133 and 180-30) and 2 AR negative (MDA-PCa-144 and 155) PDX grown in intact male mice. In vivo hyperpolarized MRI of each PDX was performed at a tumor volume of ~1.0 cm3 using 1-[13C]-pyruvate conversion to 1-[13C]-lactate. Ex vivo measurement of glycolytic metabolites, lactate, tricarboxylic acids and unique cancer metabolites were determined using NMR and mass spectrometry. We found increased glycolysis and alterations in other bioenergy metabolites in AR-positive PDX models and in low androgen environment (castration) versus AR-negative models. Our research supports the potential of hyperpolarized metabolic imaging in determining the underlying biology and in vivo phenotyping of CRPC.  

Learning Objectives:

  • the link between hyperpolarized imaging and quantitative mass spectrometry – proof of principle
  • metastatic prostate cancer being a diverse disease
  • analytical instrumentation in diagnostic and predictive marker development

 

For Research Use Only. Not for use in diagnostic procedures.

 


Show Resources
You May Also Like
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
JUL 15, 2021 9:00 AM PDT
JUL 15, 2021 9:00 AM PDT
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
DEC 05, 2017 6:00 AM PST

WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

Sponsored by: Agilent


Show Resources
Loading Comments...
Show Resources